Abstract Introduction and Objectives: Patients (pts) with moderate plaque psoriasis are often
inadequately treated (Armstrong, 2013), and there remains an unmet medical need for an …

INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

Background: UNVEIL is the first study of apremilast in patients (pts) with moderate psoriasis
(body surface area [BSA] 5%-10%) naive to biologic and systemic therapy. Physician and pt …

Background: Plaque psoriasis (PsO) with scalp involvement occurs in 65-80% of PsO (1, 2),
yet most patients are dissatisfied with scalp topical therapies (3, 4). Apremilast, an oral …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Background/Objective: Many patients with psoriasis report that they are most bothered by
symptoms in difficult-to-treat, highly visible, pruritic areas, such as the scalp. Topical …

Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …

Background Patients with mild-to-moderate psoriasis may have substantial quality-of-life
impairment. Objective To evaluate apremilast 30 mg twice daily for mild-to-moderate …